Please assess the completion status of the following clinical trial:

Trial Title: Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* In order to be eligible for participation in this trial, the subject must:~  1. Be a healthy male or female between ages 18-55 (inclusive) at the screening visit~ 2. Have a body mass index (BMI) \>19 and \<33 (inclusive)~ 3. If a female, subject~     1. Can be of childbearing potential and must demonstrate a urine β-hCG level consistent with the nongravid state at the pretrial (screening) visit and agree to use (and/or have their partner use) an acceptable method of birth control beginning at the pretrial visit throughout the trial (including washout intervals between treatment periods) and until 2 weeks after the last dose of trial drug in the last treatment period.~    2. Can be of non-childbearing potential which is defined as: a female who is postmenopausal without menses for at least 1 year and an Follicle stimulating hormone value in the postmenopausal range upon pretrial (screening) evaluation and/or a female who is status post hysterectomy, oophorectomy or tubal ligation~    3. Must be off hormonal oral or transdermal contraceptives for at least 4 weeks prior to initial dose of trial drug~ 4. Be a nonsmoker for at least approximately 6 months~ 5. Have serum creatinine level \< 1.5 mg/dL~ 6. Have a prothrombin time (PT) and activated partial thromboplastin time (PTT) level below the upper limit of normal~ 7. Have platelet count within normal limits~ 8. Be willing to refrain from the use of anticoagulants and antiplatelet medications including aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) during the entire period of study participation~ 9. Be willing to provide written informed consent for the trial~ 10. Be willing to comply with trial restrictions~Exclusion Criteria:~1. Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary or major neurological (including stroke and chronic seizures) abnormalities or diseases~2. Has history of cancer (excluding treated cutaneous squamous or basal cell carcinoma of \>3 years previous)~3. Has history of venous or arterial thromboembolic disease~4. Has a history of clinically significant bleeding risks including prior serious head trauma~5. Has had major surgery within 6 months prior to screening visit~6. Is unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies for 2 weeks prior to trial start date until the post-trial visit~7. Is unable to refrain from using any drugs or substance known to be inhibitors or inducers of cytochrome P450 (CYP) enzymes including grapefruit products for 2 weeks prior to dosing and throughout the study, until the post-trial visit~8. Has a history of illicit drug abuse within six months prior to screening visit~9. Consumes greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer \[354 mL/12 ounces\], wine \[118 mL/4 ounces\], or distilled spirits \[29.5 mL/1 ounce\]) per day and cannot refrain from alcohol for the duration of the trial~10. Has a history of significant multiple and/or severe allergies (e.g. food, drug), or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food~11. Has known anaphylactic or severe systemic reactions to any components of study drugs (including heparin induced thrombocytopenia) or contraindication to the administration of PCC or any other related blood products.~12. Has moderate or severe hepatic disease or other clinically relevant bleeding risk~13. Has positive history for hepatitis B surface antigen, hepatitis C or HIV~14. Has first degree relatives with history of bleeding disorder or hypercoagulable disease~15. Use of any drugs or products which at the discretion of the investigator would increase bleeding risk~16. Is considered inappropriate for participation by the investigator for any reason

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Apixaban with Kcentra (Type: ACTIVE_COMPARATOR): Oral apixaban will be administered to steady state in healthy volunteers followed by a single infusion of prothrombin complex concentrate Kcentra at 25 units/Kg
- Apixaban with placebo (Type: PLACEBO_COMPARATOR): Oral apixaban will be administered to steady state in healthy volunteers followed by a single infusion of saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete